###### Appendix 1: RHC and acute vasodilator protocol

**Pulmonary Hypertension**

Right Heart Catheterization and Acute Vasodilator Protocol

Insert a pulmonary artery floating catheterDo hemodynamics readings on room air, which include: RAP, mPAP, PVR, COP/CI (use refrigerated saline), PAWP\*, SaO~2~, SvO~2~, Systemic BPIf the patient is hypoxic (SaO~2~ \< 90% on room air) repeat the same hemodynamics on O~2~If PAWP is \<15 and diastolic dysfunction is clinically suspected, give 500 cc of normal saline, and repeat PAWP.If the patient has IPAH (or CHD, CTEPH), then proceed to the next step:

**\*PAWP measurement:**

PAWP should be correctly zeroed and referenced. The referencing (or leveling) is achieved by placing the air-fluid interface of the transducer at the intersection of a frontal plane passing midway between the anterior and posterior surface of the chest and a transverse plane lying at the junction of the 4th intercostal space and the sternal margin.PAWP should be measured at end-expirationIf PAWP cannot be correctly measured, LVEDP should be obtained

###### Appendix 2: SAPH protocol for PH diagnostic algorithm

**\_\_\_\_\_ Form 1 \_\_\_\_\_**

**Patient AND diagnostic data**

**Patient Name:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Patient Serial Number:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 {#sec1-1}

Patient Data {#sec2-1}
------------

**Gender: M ◻ F ◻** **Region:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**Date of Birth:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Place of Birth:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Nationality: Saudi ◻ Non-Saudi ◻**

Diagnosis of Pulmonary Hypertension {#sec1-2}
===================================

**Diagnosis made:** Yes ◻ No ◻

**By:** Echo ◻ Cath ◻

**Other** ◻

**PH clinical group:**

Group I ◻ Subtype:Group I' ◻Group I" ◻Group II ◻Group III ◻Group IV ◻Group V ◻

Symptoms {#sec2-2}
--------

Shortness of Breath: Yes ◻ No ◻

Palpitation: Yes ◻ No ◻

Cough: Yes ◻ No ◻

Chest pain: Yes ◻ No ◻

Pre-syncope: Yes ◻ No ◻

Syncope: Yes ◻ No ◻

Dizziness: Yes ◻ No ◻

Hemoptysis: Yes ◻ No ◻

Duration of Symptoms: Year

Modified NYHA Functional Class {#sec2-3}
------------------------------

Class I ◻ (no or minimal symptoms) ![](ATM-9-131-g003.jpg)

Class II ◻ (Symptoms with moderate exercise) ![](ATM-9-131-g004.jpg)

Class III ◻ (Symptoms with minimal exercise) ![](ATM-9-131-g005.jpg)

Class IV ◻ (Symptoms with any activities) ![](ATM-9-131-g006.jpg)

Signs {#sec2-4}
-----

Ht (cm): \_\_\_\_\_\_\_\_ Wt (Kg): \_\_\_\_\_\_\_\_ BMI: \_\_\_\_\_\_\_\_

Pulmonary {#sec2-5}
---------

Cyanosis: Y ◻ N ◻

Crackles: Y ◻ N ◻

Wheeze: Y ◻ N ◻

GI {#sec2-6}
--

Ascites: Y ◻ N ◻

Hepatomegaly: Y ◻ N ◻

Splenomegaly: Y ◻ N ◻

Cardiovascular {#sec2-7}
--------------

Systolic BP: \>120 ◻ 120-90 ◻ \<90 ◻

JVP: ◻

LL edema: ◻

Loud P2: ◻

Para-sternal Heave: ◻

Pulse: Regular ◻ Irregular ◻

Murmur: Systolic ◻ Diastolic ◻ Both ◻

###### Appendix 2: SAPH protocol for PH diagnostic algorithm

**\_\_\_\_\_ Form 1 \_\_\_\_\_**

**Patient AND diagnostic data**

**Patient Name:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Patient Serial Number:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 {#sec2-8}

Patient Data {#sec2-9}
------------

**Gender: M ◻ F ◻** **Region:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**Date of Birth:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Place of Birth:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Nationality: Saudi ◻ Non-Saudi ◻**

Diagnosis of Pulmonary Hypertension {#sec1-3}
===================================

**Diagnosis made:** Yes ◻ No ◻

**By:** Echo ◻ Cath ◻

**Other** ◻

**PH clinical group:**

Group I ◻ Subtype:Group I' ◻Group I" ◻Group II ◻Group III ◻Group IV ◻Group V ◻

Symptoms {#sec2-10}
--------

Shortness of Breath: Yes ◻ No ◻

Palpitation: Yes ◻ No ◻

Cough: Yes ◻ No ◻

Chest pain: Yes ◻ No ◻

Pre-syncope: Yes ◻ No ◻

Syncope: Yes ◻ No ◻

Dizziness: Yes ◻ No ◻

Hemoptysis: Yes ◻ No ◻

Duration of Symptoms: Year

Modified NYHA Functional Class {#sec2-11}
------------------------------

Class I ◻ (no or minimal symptoms) ![](ATM-9-131-g007.jpg)

Class II ◻ (Symptoms with moderate exercise) ![](ATM-9-131-g008.jpg)

Class III ◻ (Symptoms with minimal exercise) ![](ATM-9-131-g009.jpg)

Class IV ◻ (Symptoms with any activities) ![](ATM-9-131-g010.jpg)

Signs {#sec2-12}
-----

Ht (cm): \_\_\_\_\_\_\_\_ Wt (Kg): \_\_\_\_\_\_\_\_ BMI: \_\_\_\_\_\_\_\_

Pulmonary {#sec2-13}
---------

Cyanosis: Y ◻ N ◻

Crackles: Y ◻ N ◻

Wheeze: Y ◻ N ◻

GI {#sec2-14}
--

Ascites: Y ◻ N ◻

Hepatomegaly: Y ◻ N ◻

Splenomegaly: Y ◻ N ◻

Cardiovascular {#sec2-15}
--------------

Systolic BP: \>120 ◻ 120-90 ◻ \<90 ◻

JVP: ◻

LL edema: ◻

Loud P2: ◻

Para-sternal Heave: ◻

Pulse: Regular ◻ Irregular ◻

Murmur: Systolic ◻ Diastolic ◻ Both ◻

**Form 2**

**Investigational data**

General Investigations {#sec1-4}
======================

Hematology {#sec2-16}
----------

Hb: HCT: INR:

Renal Profile: {#sec2-17}
--------------

BUN: Creatinine:

Hepatic Profile {#sec2-18}
---------------

Bilirubin: ALT:

AST: Viral screen:

Immune Screen {#sec2-19}
-------------

RF: Positive ◻ Neg ◻ Titer: \_\_\_\_\_\_

ANA Positive ◻ Neg ◻ Titer: \_\_\_\_\_\_

Schistosoma: Positive ◻ Neg ◻ Titer: \_\_\_\_\_\_

HIV 1-2: Positive ◻ Neg ◻

Sickle Cell: Positive ◻ Neg ◻

Thyroid: TSH: Antibody: Positive ◻

Neg ◻

Coagulopathy {#sec2-20}
------------

Protein C: Normal ◻ Low ◻

Protein S: Normal ◻ Low ◻

Anti - phospholipid: Normal ◻ High ◻

D -- Dimer: Normal ◻ High ◻ Titer: \_\_\_\_\_\_

Factor V Laiden: Present ◻ Absent ◻

Homocystinuria: Present ◻ Absent ◻

Other Tests {#sec2-21}
-----------

NT-pro BNP: BNP: Troponin: Uric acid:

Specific Investigations {#sec2-22}
=======================

Pulmonary {#sec2-23}
---------

Arterial Blood Gases on room air

pH: PCO~2~: PO~2~: HCO~3~: O~2~ Sat:

### 6-MWT {#sec3-1}

Distance (m):

O~2~ Sat: Pre: Post: FiO~2~:

Borg Scale: Pre: Post:

### Pulmonary Function Test {#sec3-2}

FEV~1~: % Predicted FVC: % Predicted

FEV~1~/FVC: % Predicted DLco: % Predicted

### Cardiopulmonary Exercise Test {#sec3-3}

VO~2~Max: % Predicted

Anaerobic Threshold: % Predicted

Ventilatory Parameters: VE: V~D~/V~t~: RR:

Cardiac Parameters: BP: PR: O~2~

Pulse:

Respiratory Limitation: Y ◻ N ◻

Cardiac Limitation: Y ◻ N ◻

Cardiac {#sec2-24}
-------

### ECG {#sec3-4}

Sinus Rhythm: ◻ Sinus Tachycardia: ◻

Arrhythmia: ◻ Type: ◻

Right Heart Strain: ◻ (RBBB, Right Axis, RVH, P Pulmonale)

Other Abnormality:

### Echo {#sec3-5}

LVF: EF%:

RV Size and Function: Normal ◻ Abnormal ◻

PAPs: Pericardial Effusion: ◻

Diastolic Dysfunction: ◻

TAPSE: Tei Index: RV Diameter: RA Area:

Other:

### Cardiac Catheterization {#sec3-6}

mPAP: PVR: RAP:

CO: CI: Methods:

Thermodilution: ◻ Fick method: ◻

PAWP: LVEDP:

SaO~2~: SVO~2~:

Vasoreactive test: Positive ◻ Negative ◻ Agent used:

### Imaging {#sec3-7}

U/S Duplex Leg Study: Positive ◻ Negative ◻

Distal ◻ Proximal ◻

Unilateral ◻ Bilateral ◻

V/Q Scanning

Diagnostic: Yes ◻ No ◻

High probability: Yes ◻ No ◻

Other:

Chest CT Scan {#sec2-25}
-------------

### Spiral CT Angiography {#sec3-8}

Positive ◻ Negative ◻

Central ◻ Peripheral ◻

Other:

### HRCT {#sec3-9}

ILD ◻ Emphysema ◻

Other

### Pulmonary Angiography {#sec3-10}

Positive ◻ Negative ◻

Central ◻ Peripheral ◻

Other:

###### Appendix 3: SAPH 6-MWT protocol

**Name:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**MRN:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Age:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Sex:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Height:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Weight:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Nationality:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Smoker:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Date:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Time:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Diagnosis:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Attending:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Technician:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Medication:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**FIO2:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

###### Appendix 4: Criteria for Specialized Pulmonary Hypertension Center

Pulmonary Hypertension Specialized Center {#sec1-5}
=========================================

 {#sec2-26}

### Center of Excellence {#sec3-11}

PAH is a rare disease with progressive deterioration and complex management strategy. PAH patients should be managed at highly specialize center with multidisciplinary services and experience staff.

The aim of such centers is to undertake full assessment, initial investigation, and specific management of PAH patients by applying evidence-based diagnostic algorithm and offering PAH-target therapy by expert team in order to obtain best outcome.

PAH center should have a high volume of patients on chronic PAH therapy and accepting newly referred patients.

The following criteria are suggested for pulmonary hypertension specialized center, modified to comply with Saudi health system facilities:

Staff {#sec2-27}
-----

At least 2 PH consultant physicians specialists (usually from pulmonary and cardiology services)

Cardiologist with extensive experience in RHC study and hemodynamic studiesIntensivist with special interest in PH ventilated patientsAt least 1 registered nurse specialized in PHRadiologist with adequate experience in PH imagingCardiologist with adequate experience in PH related echocardiographyPsychologistAccess to social workers

Volume of activity {#sec2-28}
------------------

At least 50 patients with PAH or CTEPH in active follow-upAt least 2 new patients with PAH or CTEPH per month, followed up for 3 years or moreAt least 20 vasoreactivity tests in PAH per year

Experience and quality of care {#sec2-29}
------------------------------

Experience with all specific drugsRegular clinical review sessionsStandardized operating procedures for diagnosis and treatmentAssess indicators of outcome (survival)

Facilities and resources needed {#sec2-30}
-------------------------------

Specialized respiratory and cardiology departmentFully equipped ICUAdvanced echocardiography departmentCardiac hemodynamicsPulmonary function laboratoryCardiopulmonary stress testingSleep laboratoryCT and spiral-CT angiographyNuclear medicine

Facilities {#sec2-31}
----------

Specialized outpatient departmentCardiac catheterization with vasoreactivity testingAccess to all drugs specific to PAH24-h on-call coverage

Information system {#sec2-32}
------------------

Database designed for the assessment of actions taken and results

Research activity {#sec2-33}
-----------------

Referral centers should participate in collaborative clinical research in PAH, which includes phase II and phase III clinical trials

Other collaborative services {#sec2-34}
----------------------------

Rheumatology specialized cervicesHeart surgery and thoracic surgery (expertise inPulmonary endarterectomy)Lung and heart-lung transplantationCongenital heart disease specialty servicesLiver transplantation/liver hemodynamicsInvasive radiology services/pulmonary angiographyInfectious disease services (HIV unit, schistosoma)

Contact details {#sec2-35}
---------------

Saudi Association for Pulmonary Hypertension (SAPH)Website: www.saph.med.saEmail: saph.pht\@gmail.comSaudi Thoracic Society (STS)Email: saudithoracicsociety\@yahoo.comPhone number: + 9661 1 2488966Fax: + 9661 1 2487431
